12:00 AM
 | 
Jun 24, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Inecalcitol: Interim Phase II data

Interim data from an open-label, French Phase II trial in 5 evaluable patients with CLL who completed >=6 months of treatment with once-daily 2 mg oral inecalcitol showed that 1 patient achieved a reduction in blood lymphocyte counts of 50% at 6 months and of 80%...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >